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Automatic chemistry and the
human protein index
It is now technically feasible to assemble a nearly complete
index of all of the proteins (or protein subunits) of man
[1-3]. It is estimated that the human genome contains bet-
ween 30,000 and 50,000 structural genes, and that perhaps
10% of these genes are active in any given cell type. Hence
the analytical systems required for this effort must be able
to analyse quantitatively mixtures of 3,000 to 5,000 proteins
to deal effectively with single cell types, and ultimately to
resolve the entire set of up to 50,000 if the index is to be
properly constructed. Present two-dimensional electrophor-
eric systems resolve well over 2,000 proteins or protein
subunits, but do not represent as yet the limits of resolution
that can be reached. Fortunately sample requirements are
very small, being irrthe order of mg of protein for Coomassie
blue stained gels, 10#g of protein for silver staining, and,
depending on the amount of label incorporated and its
specific activity, well below the nanogram range for auto-
radiography or fluorography.
It is apparent to many workers in this field that a revolution
in medicine could occur if the thousands of spots seen can
be identified and quantitated on replicate gels with precision,
if new efficient methods could be .developed for idertffying
known enzymes and antigens in the patterns, if the analyses
could be done quickly and inexpensively in the clinical labor-
atory setting, and if the data could be analysed efficiently
using small dedicated 6omputing systems.
The types of problems which could be attacked are legion,
and initially one would attempt survey studies to find useful
disease correlations, as has been done with nearly all new
assays in the past. If it is worthwhile to examine the alter-
ations in the level of one protein such as alpha-feto-protein in
plasma in a wide variety of patients for example, then it
follows that it would be much better to be able simultaneously
to examine quantitatively 2,000 proteins in the same series of
diseases. However, this requires some readjustment in
perspective.
The first readjustment comes from the realisation that
most proteins are unknown, unnamed, and have unknown
functions. Protein isolation usually follows from the discovery
of a function or activity, and possibly a thousand human
enzymes and other proteins (2-3% of the total) have been
characterised to some degree, and a lesser number isolated in
pure form.
The second readjustment concerns the relationship of
specific protein analysis, especially of tissue proteins, to
clinical chemistry. The bulk of the tests now done indicate
changes in amount of a substance, usually of low molecular
weight. Two-dimensional protein maps in contrast, may
indicate the fundamental lesion in the form of an altered or
absent protein, i.e. may identify the cause.
The third, and in some respects, most difficult, readjust-
ment relates to the way research in disease processes may be
conducted. Some present animal research may no longer be
needed or be relevant. This follows from the thought that
most human disease is ultimately to be understood in terms
of alterations in the structure, amount, location, or time of
appearance during development of specific proteins or
protein sets. We do not believ it will be feasible to map or
index animal cells and tissues as completely as will be done
for human samples, largely because of the cost, time, and
effort involved. An exception may be primates which closely
resemble man, and which may be used to study changes in
proteins during various stages of development where human
material is difficult to obtain. Confirmatory studies on
human tissues would ultimately be required, however. To
be relevant, an animal model must be shown to be identical
or similar to a human disease in terms of the specific proteins
involved. To do-this means in many cases, that the human
disease must be largely understood. Note in addition that one
reason for using animal tissues has been that sufficient
human material was not available. The extraordinarily small
samples required for 2-D electrophoresies remove this problem.
The need for automation
While over 30,000 two-dimensional electrophoretic analyses
have already been run in this laboratory [4-5], theautomation
of the entire system is in a very primitive stage. We believe
that automation is essential to lower cost, and to obtain
reproducibility. Not only the electrophoretic step, but the
subsequent image analysis and computerised data reduction
must be made simple, automatic, and as far as possible,
miniaturised. That, however, is far from the end of the
problem. The aim is to be able to identify each protein
uniquely, to be able to distinguish it from all others found in
human cells, and to also establish identities, i.e. that a spot
seen in a 2-D brain protein gel is identical to one seen in a
kidney protein gel; or that a new protein found in a tumor
cell is really the same as one found at some stage in embryo-
genisis. To achieve these goals, it is necessary to be able to.
run very large numbers of analyses indeed.
This requirement follows from the fact that samples must
be run at several different loadings to achieve maximum
resolution, and that additional runs must be made using
internal standards for pI [6] and molecular weight [7].
Identity of spots is established in a variety of ways, including
comigration, similar amino acid analysis (obtained by analys-
ing a number of samples of the same cell labelled with different
amino acids), formation of similar carbamylation trains, and
by showing that the thermal denaturation curves are similar.
In addition single spots may be partially digested and shown
to give similar patterns in so-called Cleveland gels [8 ].
Ultimately, however, two difficult problems must be
solved. The first is the identification of spots corresponding
to all known enzymes. We have done sufficient protein
isolation using classical methods to conclude that some
other systematic approach is required. Use of thermal de-
naturation techniques has been explored, and offers promise
[9], but does not appear to be the final solution.
The second problem is that of definitive localisation of a
given protein .in one cell type found in a mixed tissue. Cell
separation is of assistance, but may not give clean cut results.
In addition, when the appearance of a protein or a set of
corregulated proteins appears during differentiation, especially
in the very early embryo, sufficient material may not be
available, and subtle difference may exist between cells
which are morphologically identical.
The obvious answer to the problem is to make antibodies,
preferably monoclonal antibodies, against as many different
proteins or protein subunits as possible. The large amount
of work required to sort out useful antibody cells from
hybridoma mixtures also calls for automation on a scale not
previously envisioned.
Pattern of biomedical research
It might be thought that an effort to produce a human
protein index, and to extend it with specific reagents (anti-
bodies) for each entry, would be an impossibly large under-
taking, difficult to manage and organise. The truth is that not
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only is it difficult, it is impossible given the traditional
modus operandi of biomedical research. It would not be
possible, for example, to launch a truly interdisciplinary
project such as this one and depend on a grant system in
which each part is separately reviewed and funded, and
where as much as a year’s delay may occur between the identi-
fication of a need, and funding to provide a solution. It is
also evident that the problem cannot be solved simply by
accretion, i.e., by hoping to compile the index from un-
correlated studies in many different laboratories. High-
energy physics mastered the art of organising and running
large collaborative ventures. In contrast, the biomedical
sciences have so far avoided them, possibly because they
were not really needed.
Now, however, we face, real!y for the first time, the true
complexity of the human cellular systems with which we
work. Extraordinary reluctance to alter the pattern or scale
of biomedical research is to be expected. It is important to
inquire briefly, therefore, into what could be gained if an
intensive effort to produce a human protein index were
made, and what would be the alternative.
Of central importance are the annotations which will
accompany each numbered entry in the human protein index.
These would include (following the gel spot number):
10.
11.
12.
1. The sample source.
2. Molecular weight (actual position on an SDS gel).
3. Isoelectric point.
4. Name or function where known.
5. Subcellular localisation of the protein.
6. Associated subunits if a multimeric protein.
7. Identification of the coregulational set to which a
protein belongs.
8. Chromosomal location of the structural gene for the
protein or protein subunit.
Variants of a peptide and their correlation with disease.
Spot co-ordinates on a standardised reference map.
Notes including all .observations relative to a peptide
including response to experimental variable.
Corresponding master human protein index number.
We describe elsewhere the rules and rationale for initial
number of spots on gels, and we propose to delay for some
time the assignment of master numbers. Obviously the index
can be searched from the viewpoint of any class of entry.
One could, for example, obtain a list of all of the proteins
known to be coded for by genes on chromosome I.
For the purposes of this discussion the important points
are that proteins and protein sets characteristic of discrete
cell types, of stages in development, of germ layers, and very
probably of a number of disease states will be discoverable
by searching through the index data base [10]. Of special
interest is the problem of corregulated sets. Are genes expres-
sed, (for this discussion lumping together all stages and pro-
cesses between DNA and protein) in sets or batteries, and are
these sets expressed in a precise order during development?
In cancer, are sets characteristic of early developmental
stages turned back on? These are questions which cannot
be answered without the mass of analytical data necessary to
form the index.
The alternative is to slowly explore human cells by
classical techniques, isolating one protein after another, and
exploring its relation to disease in a laborious fashion. As
correlations with disease are discovered, new immunoassays
can then be developed. Given tens of thousands of proteins
to explore, and an almost equal number of diseases to corre-
late each one with, such an approach will be time consuming
and ultimately very expensive indeed.
The most compelling argument for the more global
approach offered by analytical systems which ’see’ a very
large number of discrete entities at a time comes from simple
statistical considerations. If one causal anomalous protein is
to be discovered in a set of 30,000 for example, there is a
1% chance that it will be among the first 1% examined by
classical methods, and there is an equal chance that it will be
among the last 1% studied.
Further, the prospect of analysing samples from. patients
with thousands of different diseases (over 2,000 human
genetic diseases are known) one protein at a time is dismal
indeed.
We rather tend to the view that a well planned and inte-
grated attempt to develop automatic systems for sample
preparation, for two-dimensional electrophoresis, for spot
identification, for image analysis and data reduction, for
hybridoma cell selection, and for computerised search
programs to find correlations between patterns or variants
and disease would in the end contribute not only to more
precise diagnosis, but to the evaluation of therapy, and to
the discovery of new protein replacement therapies.
Norman G. Anderson and Leigh Anderson
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